Phase 3 clinical trial of paclitaxel and atezolizumab shows no significant survival benefit, but questions remain over FDA decision to issue safety alert. In 2019, the FDA granted accelerated approval ...
The SC formulation is designed to improve patient convenience, reducing the time of administration from several hours to 5 minutes. Rybrevant Faspro is a combination of amivantamab, a bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback